INBRX-106 Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for INBRX-106 comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Head and Neck Neoplasms. Most recent publication: INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering., J Immunother Cancer, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.
    Holay N, Yadav R, Ahn SJ, et al. · J Immunother Cancer · 2025
    PubMed: PMID 40404202 · NCT04198766 · Head and Neck Neoplasms

Publications by year

2025–2025: 1 publications.

2025
1

Publications by indication

Head and Neck Neoplasms (1)

  • INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.
    J Immunother Cancer · 2025 · PMID 40404202 · NCT04198766

Publications by journal

  • J Immunother Cancer1 paper

All INBRX-106 publications (1)

2025 (1 paper)

  1. INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.
    Holay N, Yadav R, Ahn SJ, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40404202 · NCT04198766 · Head and Neck Neoplasms

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Fri, 17 Jul 2026 04:08:08 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).